|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 January 2003, Vol. 101, No. 2, pp. 420-424
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Treatment of relapsed CD20+ Hodgkin lymphoma with the
monoclonal antibody rituximab is effective and well tolerated: results
of a phase 2 trial of the German Hodgkin Lymphoma Study
Group
Ute Rehwald,
Holger Schulz,
Marcel Reiser,
Markus Sieber,
Jan Oliver Staak,
Franck Morschhauser,
Christoph Driessen,
Thomas Rüdiger,
Konrad Müller-Hermelink,
Volker Diehl, and
Andreas Engert on behalf of the German
Hodgkin Lymphoma Study Group (GHSG)
From the Department I of Internal Medicine, University
of Cologne, Cologne, Germany; Centre Hospitalier Regional
Universitaire de Lille, France; Medizinische Klinik und
Poliklinik II, Universitätsklinikum Tübingen,
Germany; and the Department of Pathology, University
Wuerzburg, Germany.
This phase 2 trial was performed to evaluate the safety and
efficacy of the chimeric monoclonal anti-CD20 antibody rituximab in
patients with relapsed lymphocyte-predominant Hodgkin lymphoma or other CD20+ subtypes of Hodgkin disease (HD).
Eligibility criteria required expression of the CD20 antigen on more
than 30% of malignant cells. Fourteen patients were treated with 4 weekly intravenous infusions of rituximab (375 mg/m2). All
patients had at least one prior chemotherapy (median, 2). The median
time from first diagnosis was 9 years. Adverse events, such as
rhinitis, fever, chills, and nausea, were usually transient and of mild
to moderate grade, allowing outpatient treatment in most cases. All
patients completed treatment and were eligible for a response. The
overall response in 14 assessable patients was 86%, with 8 complete
remissions and 4 partial remissions, and 2 patients with progressive
disease. At a median follow-up of 12 months, 9 of 12 responders were in
remission. The median duration of response has not been reached
yet (20+ months). We conclude that rituximab is both safe and effective
in a subgroup of CD20+ patients with HD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Nogova, T. Reineke, C. Brillant, M. Sieniawski, T. Rudiger, A. Josting, H. Bredenfeld, R. Skripnitchenko, R.-P. Muller, H.-K. Muller-Hermelink, et al.
Lymphocyte-Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
J. Clin. Oncol.,
January 20, 2008;
26(3):
434 - 439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schulz, U. Rehwald, F. Morschhauser, T. Elter, C. Driessen, T. Rudiger, P. Borchmann, R. Schnell, V. Diehl, A. Engert, et al.
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Blood,
January 1, 2008;
111(1):
109 - 111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Brusamolino and A. M. Carella
Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives
Haematologica,
January 1, 2007;
92(1):
6 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Nogova, T. Rudiger, and A. Engert
Biology, Clinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Hematology,
January 1, 2006;
2006(1):
266 - 272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Nogova, T. Reineke, H. T. Eich, A. Josting, H. K. Muller-Hermelink, K. Wingbermuhle, C. Brillant, A. Gossmann, J. Oertel, M. V. Bollen, et al.
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)
Ann. Onc.,
October 1, 2005;
16(10):
1683 - 1687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Re, R. K. Thomas, K. Behringer, and V. Diehl
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
Blood,
June 15, 2005;
105(12):
4553 - 4560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Feugier, E. Labouyrie, M. Djeridane, A. Jenabian, V. Dubruille, C. Berthou, C. Ghandour, B. Desablens, Y. Chait, P. Casassus, et al.
Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation
Blood,
November 1, 2004;
104(9):
2675 - 2681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors
Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hematology,
January 1, 2003;
2003(1):
225 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
